S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
LON:SBTX

SkinBioTherapeutics - SBTX Share Forecast, Price & News

GBX 20.75
-0.50 (-2.35%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
20.63
21.95
50-Day Range
15.16
22.63
52-Week Range
15
54.40
Volume
407,932 shs
Average Volume
390,391 shs
Market Capitalization
£32.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SBTX stock logo

About SkinBioTherapeutics (LON:SBTX) Stock

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health. It develops SkinBiotix technology that can enhance the formation of multi-protein complexes and prevent passage toxins, molecules, and ions, as well as pathogens; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has a collaboration agreement with Croda Plc; and the University of Manchester to develop bacterial lysates in the prevention of periodontal gun disease. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

Receive SBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SkinBioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SBTX Stock News Headlines

SkinBioTherapeutics to Raise a Minimum of GBP2.5 Mln
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
SkinBioTherapeutics CFO to Step Down
SkinBioTherapeutics : Result of AGM
SkinBioTherapeutics : Notice of Results
SkinBioTherapeutics : Placing of Shares
SkinBioTherapeutics Launches Discounted Share Placing
SkinBioTherapeutics : AxisBiotix-PsT Psoriasis Food Supplement Launch
SkinBioTherapeutics : Holding(s) in Company
SkinBioTherapeutics Plc (SBTX.L)
SkinBioTherapeutics : Exercise of Warrant
See More Headlines
Receive SBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SkinBioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SBTX Company Calendar

Last Earnings
3/03/2020
Today
2/04/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£21,949.00
Cash Flow
GBX 2.31 per share
Book Value
GBX 2.70 per share

Miscellaneous

Free Float
N/A
Market Cap
£32.53 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Stuart John Ashman (Age 56)
    CEO & Exec. Director
    Comp: $325.85k
  • Mr. Manprit Singh Randhawa (Age 39)
    CFO, Sec. & Director
    Comp: $177.98k
  • Dr. Catherine O'Neill
    Chief Scientific Officer & Member of Scientific Advisory Board













SBTX Stock - Frequently Asked Questions

How have SBTX shares performed in 2023?

SkinBioTherapeutics' stock was trading at GBX 15.50 at the start of the year. Since then, SBTX shares have increased by 33.9% and is now trading at GBX 20.75.
View the best growth stocks for 2023 here
.

How were SkinBioTherapeutics' earnings last quarter?

SkinBioTherapeutics Plc (LON:SBTX) posted its earnings results on Tuesday, March, 3rd. The company reported ($0.64) earnings per share for the quarter.

What other stocks do shareholders of SkinBioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SkinBioTherapeutics investors own include Avacta Group (AVCT), Inspired (INSE), OptiBiotix Health (OPTI), Lb-shell (LBP), Anglo African Oil & Gas (AAOG), Big Sofa Technologies Group (BST), Concepta PLC (CPT.L) (CPT), Fresnillo (FRES) and Shield Therapeutics (STX).

What is SkinBioTherapeutics' stock symbol?

SkinBioTherapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SBTX."

How do I buy shares of SkinBioTherapeutics?

Shares of SBTX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is SkinBioTherapeutics' stock price today?

One share of SBTX stock can currently be purchased for approximately GBX 20.75.

How much money does SkinBioTherapeutics make?

SkinBioTherapeutics (LON:SBTX) has a market capitalization of £32.53 million and generates £21,949.00 in revenue each year.

How can I contact SkinBioTherapeutics?

SkinBioTherapeutics' mailing address is 15 1 Silk House, Park Green, MACCLESFIELD, SK11 7QJ, United Kingdom. The official website for the company is www.skinbiotherapeutics.com. The company can be reached via phone at +44-161-4682760.

This page (LON:SBTX) was last updated on 2/5/2023 by MarketBeat.com Staff